• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

8AK:GR

31.125 EUR 1.165 3.89%

As of 02:04:10 ET on 04/16/2014.

Snapshot for Alkermes PLC (8AK)

Open: 31.110 Day's Range: 31.110 - 31.125 Volume: 0
Previous Close: 29.960 52wk Range: 18.550 - 39.315 1-Yr Rtn: +64.51%

Stock Chart for 8AK

No chart data available.
  • 8AK:GR 31.125
  • 1D
  • 1M
  • 1Y
29.960
Interactive 8AK Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 8AK

Current P/E Ratio (ttm) 157.7821
Estimated P/E(12/2014) 84.6245
Relative P/E vs. DAX 6.7023
Earnings Per Share (USD) (ttm) 0.2730
Est. EPS (USD) (12/2014) 0.5090
Est. PEG Ratio 2.8755
Market Cap (M EUR) 4,477.44
Shares Outstanding (M) 143.85
30 Day Average Volume 89
Price/Book (mrq) 5.5720
Price/Sale (ttm) 9.7682
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/23/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 8AK

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for 8AK

Alkermes PLC researches pharmaceuticals. The Company develops treatments for central nervous system disorders such as addiction, schizophrenia and depression, and diabetes.

Richard F PopsChairman/CEOShane CookePresident
James M Frates "Jim"Senior VP/CFO/TreasurerGordon G PughSenior VP/COO/Chief Risk Ofcr
More Company Profile & Key Executives for 8AK

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil